MLTX N Stock Overview
A clinical-stage biopharmaceutical company, engages in developing therapies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MoonLake Immunotherapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$977.05 |
| 52 Week High | US$1,029.82 |
| 52 Week Low | US$750.00 |
| Beta | 1.19 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 7.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| MLTX N | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how MLTX N performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how MLTX N performed against the MX Market.
Price Volatility
| MLTX N volatility | |
|---|---|
| MLTX N Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: MLTX N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MLTX N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 50 | Jorge da Silva | www.moonlaketx.com |
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics Fundamentals Summary
| MLTX N fundamental statistics | |
|---|---|
| Market cap | Mex$48.82b |
| Earnings (TTM) | -Mex$592.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-82.4x
P/E RatioIs MLTX N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MLTX N income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$36.01m |
| Earnings | -US$36.01m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.57 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MLTX N perform over the long term?
See historical performance and comparison